European Academy of Dermatology and Venereology Congress

MILAN — Vitiligo treatment was found to cause greater stress in women than men, and treatment burden was greater in those with darker vs. fairer skin, according to a study presented here.

MILAN — Patients with psoriasis who initially responded to bimekizumab maintained that response through 3 years with maintenance dosing, according to an open label long-term extension trial

MILAN — Long-term treatment with risankizumab maintained efficacy in psoriatic arthritis through 100 weeks, according to a study presented at the European Academy of Dermatology and Venereology Congress.

MILAN — In patients with seborrheic dermatitis, once-daily roflumilast foam had a significant impact on skin clearance and itch response and was tolerated well, according to phase 3 trial results.

For allergists interested in dermatology-focused findings from the European Academy of Dermatology and Venereology Congress but who could not attend the meeting this year in Milan, Healio presents this list of seven studies that may be relevant to your practice.

MILAN — Severity of alopecia areata as well as scalp hair regrowth continued to improve with treatment at 48 weeks in further analysis of data from the ALLEGRO trial, according to a poster presented here.

MILAN — Patients who underwent re-excision for positive margins after incomplete surgery for basal cell carcinoma had significantly lower recurrence rates than those who were followed up clinically, according to a poster presented here.

MILAN — Long-pulsed alexandrite laser yielded comparable results to pulsed-dye laser in the treatment of rosacea in a 7-month study.

MILAN — Brodalumab proved to be an effective treatment for Japanese patients with palmoplantar pustulosis in a 16-week phase 3 trial.

MILAN — Deucravacitinib demonstrated efficacy and safety in treating patients with systemic lupus erythematosus and sustained improvement up to 48 weeks.